A $21.3M Bet on a Breast Reconstruction Alternative That Grows With the Patient

Jan de Vries · 2026-09-03

When you hear about breast reconstruction after cancer surgery, the conversation usually centers on implants or tissue flaps. But a Milan-based startup called Tensive is taking a completely different path—one that lets a woman's own body rebuild the tissue that was removed during a lumpectomy. And now, the European Investment Bank (EIB) is backing that vision with a hefty convertible loan of $21.3 million (€20 million). That funding isn't just a pat on the back. It's a vote of confidence in REGENERA, a bioresorbable scaffold that acts like a temporary framework. Once placed in the surgical cavity, it gradually dissolves as the patient's own healthy tissue grows in to replace it. No second surgery. No permanent foreign object. Just the patient's own biology doing the heavy lifting. ### What Exactly Is REGENERA? Imagine a sponge-like material that feels similar to natural adipose tissue. During a lumpectomy, the surgeon places REGENERA right into the cavity left behind. Because it's soft and adaptable, it conforms to the space without needing manual size adjustments. That means the procedure stays quick, convenient, and low-risk. But here's the real kicker: over time, the body absorbs the scaffold and replaces it with natural tissue. The result is breast restoration that maintains the patient's original shape and feel—something no implant can truly replicate. Plus, because REGENERA is clearly visible on diagnostic imaging, it helps doctors target radiotherapy more precisely and makes follow-up surveillance far more accurate.  ### The Financial Backing and What It Means The EIB loan is part of a broader $42.6 million (€40 million) financing plan, and it's supported by the EU Commission's InvestEU programme. According to Sanjay Kakkar, MD, CEO of Tensive, the bank "examined our clinical evidence and our regulatory file in detail" before committing. This isn't just a cash injection; it's a seal of approval from one of Europe's most rigorous financial institutions. The funds will fuel research and development, clinical studies, CE marking, manufacturing scale-up, and commercialization readiness. In plain English: they're getting ready to bring REGENERA to European surgeons' hands, and they need the infrastructure to do it at scale. ### A Broader Wave of European MedTech Funding Tensive isn't alone in this rally. Across Europe, investors are pouring money into regenerative medicine and medical devices. Here's a quick snapshot of recent moves: - **Xeltis** (Dutch-US): $21.8 million (€20.5 million) for vascular implants that transform into the patient's own tissue. - **FineHeart** (France): $88.4 million (€83 million) in private capital and grants for implantable cardiac devices. - **SamanTree Medical** (Belgium): $21.3 million (€20 million) in EIB financing for surgical imaging. - **ScreenPoint Medical** (Netherlands): $14.5 million (€13.6 million) for breast cancer detection tools. Italy is also getting in on the action. Pisa-based Wearable Robotics raised $5.3 million (€5 million) for rehab robotics, while Bologna's Cellply secured $7.6 million (€7.15 million) for cancer and cell-therapy analytics. ### Why This Matters for Women's Health Gelsomina Vigliotti, EIB Vice President, put it plainly: "Supporting European innovation in health, and in women's health in particular, is central to the EIB Group's mission." That's not just corporate speak. Breast cancer lumpectomy leaves many women with few viable options for reconstruction. Implants carry risks like capsular contracture and need replacement. Flap surgeries are invasive and require long recovery. REGENERA offers a middle path that's less invasive and more natural. Founded in 2012, Tensive is now one step closer to making that option a reality. The convertible loan is structured in two tranches of $8.5 million (€8 million) each, giving the company room to hit milestones before drawing the full amount. The road from clinical trials to operating rooms is long, but with this kind of backing, Tensive is well-positioned to change how we think about breast reconstruction. And for the women who've had to settle for imperfect options, that's a huge deal.